Cargando…
Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL protocol
Atrial fibrillation is a frequent complication among patients with severe coronavirus disease-2019 (COVID-19) infection. Both direct and indirect mechanisms through COVID-19 have been described to explain this relationship. COVID-19 infection increases the risk of developing both arterial and venous...
Autores principales: | Iturbe-Hernandez, Teodoro, García de Guadiana Romualdo, Luis, Gil Ortega, Ignacio, Martínez Francés, Antonio, Meca Birlanga, Olga, Cerezo-Manchado, Juan José |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505118/ https://www.ncbi.nlm.nih.gov/pubmed/33014097 http://dx.doi.org/10.7573/dic.2020-8-3 |
Ejemplares similares
-
Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL protocol
por: Cerezo-Manchado, Juan José, et al.
Publicado: (2022) -
Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the “ACO-VID” Registry
por: Cerezo Manchado, Juan José, et al.
Publicado: (2023) -
Anibal
por: Baker, George Philip, 1879-
Publicado: (1963) -
Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation
por: Liu, Ya-ou, et al.
Publicado: (2022) -
Newer Anticoagulants for Non-Valvular Atrial Fibrillation
por: Harburger, Joseph M., et al.
Publicado: (2012)